FeesSafety
Pluang+

Mortgage rates dip to 7.3%, but homebuying and refinancing demand remain low.

Market News
04 Nov 2026, 14:00 WIB
CNBC
View Source
Bearish
Mortgage rates dip to 7.3%, but homebuying and refinancing demand remain low.

Mortgage rates for 30-year fixed loans fell slightly to 7.3%, the lowest since September 2026, following the Fed's pause on rate hikes. Despite this, mortgage applications declined, with homebuyer requests down 19% year-over-year and refinancing demand 60% lower than last year. Adjustable-rate mortgages gained popularity as borrowers seek lower initial payments amid high rates. The housing market remains sluggish due to persistently elevated borrowing costs.

Mortgage rates and homebuyer activity provide context for this story. For readers following the Financials sector, here is Pluang's market snapshot as of Nov 04, 2026 19:31 WIB: out of 142 priced US Financial stocks, 110 rose and 31 fell today. Notable movers include UNM (Unum Group) down 7.89% at USD 83.85 with a typical hold time of 20 days, GLXY (Galaxy Digital) down 6.83% at USD 15.68 with 100% buy order activity and an 8-day hold, and SAN (Banco Santander) up 6.53% at USD 12.08 with a 56-day hold time and 100% buy order activity.

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
26 minutes ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
26 minutes ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
26 minutes ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
26 minutes ago
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...

Market News
Bullish
26 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App